Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.30 |
| ▸ | MITF | O75030 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6989495 | 0.82 | LMNA (0.46) | LMNAHPGDALDH1A1MAPT | |
| SCHEMBL784919 | 0.75 | CYP3A4 (0.36) | CYP3A4POLBLMNAALDH1A1TARBP2 | |
| SCHEMBL14284010 | 0.74 | CYP3A4 (0.50) | CYP3A4ATMLMNAHPGDALDH1A1 | |
| Isodillapiol SCHEMBL29378145 | 0.71 | POLB (0.49) | CYP3A4ATMPOLBLMNAHPGD | |
| SCHEMBL14284000 | 0.70 | CYP3A4 (0.38) | CYP3A4POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL14747985 | 0.69 | KDM4E (0.46) | POLBLMNAHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL16900571 | 0.69 | MEN1 (0.40) | CYP3A4HPGDALDH1A1SMN1; SMN2HSP90AA1 | |
| SCHEMBL22433011 | 0.68 | NQO2 (0.39) | CYP3A4POLBALDH1A1SMN1; SMN2TARBP2 | |
| SCHEMBL10074952 | 0.67 | SELL (0.37) | CYP3A4ESR1ESR2 | |
| SCHEMBL13972664 | 0.67 | MAOB (0.50) | CYP3A4ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249106-B2 | Substituted hydrazide compounds and use thereof | SHENYANG J & HEALTH PHARMACEUTICAL CO., LTD. (CN) | 2016-02-02 | — | — | US | disclosed |
| US-9249106-B2 | Substituted hydrazide compounds and use thereof | SHENYANG J & HEALTH PHARMACEUTICAL CO., LTD. (CN) | 2016-02-02 | — | — | US | disclosed |
| US-20120142921-A1 | SUBSTITUTED HYDRAZIDE COMPOUNDS AND USE THEREOF | SHENYANG J & HEALTH PHARMACEUTICAL CO., LTD. (CN) | 2012-06-07 | — | — | US | disclosed |
| US-20120142921-A1 | SUBSTITUTED HYDRAZIDE COMPOUNDS AND USE THEREOF | SHENYANG J & HEALTH PHARMACEUTICAL CO., LTD. (CN) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142921-A1 | SUBSTITUTED HYDRAZIDE COMPOUNDS AND USE THEREOF | SLC5A1, VHL, AKR1A1 | CYP3A4 99/4885ATM 2606/4885POLB 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.